DE69617211T2 - Hepatitis b impfstoff - Google Patents

Hepatitis b impfstoff

Info

Publication number
DE69617211T2
DE69617211T2 DE69617211T DE69617211T DE69617211T2 DE 69617211 T2 DE69617211 T2 DE 69617211T2 DE 69617211 T DE69617211 T DE 69617211T DE 69617211 T DE69617211 T DE 69617211T DE 69617211 T2 DE69617211 T2 DE 69617211T2
Authority
DE
Germany
Prior art keywords
vaccine
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69617211T
Other languages
English (en)
Other versions
DE69617211D1 (en
Inventor
Pierre Hauser
Marie-Josephe Garcon
Pierre Desmons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10770292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69617211(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline Biologicals SA, SmithKline Beecham Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of DE69617211D1 publication Critical patent/DE69617211D1/de
Application granted granted Critical
Publication of DE69617211T2 publication Critical patent/DE69617211T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69617211T 1995-02-25 1996-02-15 Hepatitis b impfstoff Expired - Lifetime DE69617211T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9503863.4A GB9503863D0 (en) 1995-02-25 1995-02-25 Vaccine compositions
PCT/EP1996/000681 WO1996026741A1 (en) 1995-02-25 1996-02-15 Hepatitis b vaccine

Publications (2)

Publication Number Publication Date
DE69617211D1 DE69617211D1 (en) 2002-01-03
DE69617211T2 true DE69617211T2 (de) 2002-07-25

Family

ID=10770292

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69617211T Expired - Lifetime DE69617211T2 (de) 1995-02-25 1996-02-15 Hepatitis b impfstoff

Country Status (36)

Country Link
US (1) US5972346A (de)
EP (1) EP0810877B1 (de)
JP (1) JP3881015B2 (de)
KR (1) KR100365373B1 (de)
CN (1) CN1101225C (de)
AP (1) AP766A (de)
AR (1) AR002279A1 (de)
AT (1) ATE209045T1 (de)
AU (1) AU695921B2 (de)
BG (1) BG101851A (de)
BR (1) BR9607458A (de)
CA (1) CA2212552C (de)
CZ (1) CZ288417B6 (de)
DE (1) DE69617211T2 (de)
DK (1) DK0810877T3 (de)
EA (1) EA199700126A1 (de)
ES (1) ES2166879T3 (de)
FI (1) FI118118B (de)
GB (1) GB9503863D0 (de)
HK (1) HK1004117A1 (de)
HU (1) HU224832B1 (de)
IL (1) IL117249A (de)
MA (1) MA23814A1 (de)
MX (1) MX9706450A (de)
MY (1) MY113428A (de)
NO (1) NO319394B1 (de)
NZ (1) NZ302674A (de)
OA (1) OA10612A (de)
PL (1) PL182679B1 (de)
PT (1) PT810877E (de)
SA (1) SA96160633B1 (de)
SK (1) SK115097A3 (de)
TR (1) TR199700849T1 (de)
TW (1) TW467745B (de)
WO (1) WO1996026741A1 (de)
ZA (1) ZA961460B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620414B2 (en) * 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6488934B1 (en) * 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
US20010014331A1 (en) * 1996-11-07 2001-08-16 Smithkline Beecham Biologicals S.A. Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
US20030049268A1 (en) 1998-05-01 2003-03-13 Smithkline Beecham Biologicals S.A. Novel composition
GB9809507D0 (en) * 1998-05-01 1998-07-01 Smithkline Beecham Biolog Novel composition
DE69932717T2 (de) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa Methoden und produkte zur induzierung mukosaler immunität
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
EP1126876B1 (de) 1998-10-16 2007-03-21 GlaxoSmithKline Biologicals S.A. Adjuvanzsysteme und impfstoffe
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
WO2000037104A1 (en) * 1998-12-23 2000-06-29 Merck & Co., Inc. Improved recombinant hepatitis b surface antigen
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
AP2007004151A0 (en) * 2005-02-16 2007-10-31 Norvatis Vaccines And Diagnost Adjuvant composition comprising aluminium phosphate and 3D-MPL
WO2007015167A2 (en) * 2005-08-02 2007-02-08 Novartis Vaccines And Diagnostics Srl Reducing interference between oil-containing adjuvants and surfactant-containing antigens
CA2628328A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
PL2368572T3 (pl) 2005-11-04 2020-11-16 Seqirus UK Limited Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
JP2009514839A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
NZ567978A (en) 2005-11-04 2011-09-30 Novartis Vaccines & Diagnostic Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
CN100415294C (zh) * 2005-12-23 2008-09-03 中国农业大学 一种治疗和/或预防乙肝的药物
EP3753574A1 (de) 2006-01-27 2020-12-23 Seqirus UK Limited Influenzaimpfstoffe mit hämagglutinin und matrixproteinen
EP2010537B1 (de) 2006-03-23 2011-12-28 Novartis AG Imidazochinoxalinverbindungen als immunmodulatoren
WO2007110776A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
EP1862176A1 (de) * 2006-05-31 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
EP1862177A1 (de) * 2006-06-01 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
NZ575271A (en) 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009081172A1 (en) 2007-12-24 2009-07-02 Novartis Ag Assays for adsorbed influenza vaccines
PL3178490T3 (pl) 2009-07-15 2022-08-01 Glaxosmithkline Biologicals S.A. Kompozycje białka f rsv i sposoby ich wytwarzania
EP4144368A1 (de) 2011-01-26 2023-03-08 GlaxoSmithKline Biologicals S.A. Rsv-immunisierungstherapie
US9452212B2 (en) 2011-04-14 2016-09-27 Dynavax Technologies Corporation Methods and compositions for eliciting an immune response against hepatitis B virus
WO2012158613A1 (en) 2011-05-13 2012-11-22 Novartis Ag Pre-fusion rsv f antigens
EP3313439A2 (de) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenetisch angepasste influenza-impfstoffe

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE159031T1 (de) * 1989-07-25 1997-10-15 Smithkline Biolog Antigene sowie verfahren zu deren herstellung
EP0835639A3 (de) * 1991-05-29 1999-04-07 Origin Medsystems, Inc. Retraktor-Vorrichtung für endoskopische Chirurgie
MA22842A1 (fr) * 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
CZ283910B6 (cs) * 1992-05-23 1998-07-15 Smithkline Beecham Biologicals (S.A.) Kombinovaný očkovací prostředek, způsob jeho výroby a použití fosforečnanu hlinitého jako pomocného prostředku
ES2162139T5 (es) * 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
GB9311536D0 (en) * 1993-06-04 1993-07-21 Unilever Plc Hot soluble low density extractable food product

Also Published As

Publication number Publication date
AU4878096A (en) 1996-09-18
IL117249A (en) 2000-11-21
WO1996026741A1 (en) 1996-09-06
MX9706450A (es) 1998-07-31
GB9503863D0 (en) 1995-04-19
EA199700126A1 (ru) 1998-02-26
BG101851A (en) 1998-04-30
TW467745B (en) 2001-12-11
KR19980702480A (ko) 1998-07-15
CZ267497A3 (cs) 1998-02-18
AU695921B2 (en) 1998-08-27
KR100365373B1 (ko) 2003-07-07
FI973457A0 (fi) 1997-08-22
CA2212552C (en) 2006-07-11
HU224832B1 (en) 2006-03-28
DK0810877T3 (da) 2002-02-25
NZ302674A (en) 1999-01-28
SK115097A3 (en) 1998-02-04
PT810877E (pt) 2002-04-29
CN1101225C (zh) 2003-02-12
CA2212552A1 (en) 1996-09-06
BR9607458A (pt) 1998-06-30
US5972346A (en) 1999-10-26
AR002279A1 (es) 1998-03-11
EP0810877B1 (de) 2001-11-21
DE69617211D1 (en) 2002-01-03
HUP9801242A1 (hu) 1998-08-28
JPH11501018A (ja) 1999-01-26
PL321966A1 (en) 1998-01-05
OA10612A (en) 2002-08-29
PL182679B1 (pl) 2002-02-28
FI118118B (fi) 2007-07-13
EP0810877A1 (de) 1997-12-10
MY113428A (en) 2002-02-28
SA96160633B1 (ar) 2005-10-15
NO973873L (no) 1997-08-22
HUP9801242A3 (en) 2000-08-28
CN1176604A (zh) 1998-03-18
ATE209045T1 (de) 2001-12-15
NO319394B1 (no) 2005-08-08
FI973457A (fi) 1997-08-22
CZ288417B6 (en) 2001-06-13
NO973873D0 (no) 1997-08-22
AP766A (en) 1999-09-17
IL117249A0 (en) 1996-06-18
HK1004117A1 (en) 1998-11-20
ES2166879T3 (es) 2002-05-01
MA23814A1 (fr) 1996-10-01
TR199700849T1 (xx) 1998-01-21
AP9701060A0 (en) 1997-10-31
JP3881015B2 (ja) 2007-02-14
ZA961460B (en) 1996-08-29

Similar Documents

Publication Publication Date Title
DE69617211T2 (de) Hepatitis b impfstoff
NO976060D0 (no) Vaksiner mot hepatitt C
NO20003302L (no) Vaksine
BR9711853A (pt) Vacinas
KR970704468A (ko) 폴리에피토프 백신(polyepitope vaccines)
ID20399A (id) Vaksin influensa
DE69126606D1 (de) Vakzine
DK0736303T3 (da) Interferonopløsning
DE69510024D1 (de) Spritze
ATE253641T1 (de) Antigenische präparationen
DE69509766D1 (de) Mikroemulsionen
IT1276662B1 (it) Vaccini polinucleotidici
NO933600D0 (no) Termostabile virus
DE29504168U1 (de) Formularsatz
ITMI950511A0 (it) Fotodensitometro parallelo perfezionato
SI0810877T1 (en) Hepatitis b vaccine
DE69326536T2 (de) Antitumor Impfstoff
FI944558A0 (fi) Virus
UA24703A (uk) Емітерний повторювач
NO980721D0 (no) Vaksiner
BR7502544U (pt) Easy baby
KR970703417A (ko) 유두종 바이러스 백신(Papillomavirus vaccines)
SE9501165D0 (sv) Hållaranordning
BR7500363U (pt) Formulário
KR960026743U (ko) 주사기

Legal Events

Date Code Title Description
8364 No opposition during term of opposition